An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 15 Mar 2017 This trial has been completed in Austria as per European Clinical Trials Database.
- 01 Jul 2015 Planned End Date changed from 1 Jul 2019 to 1 May 2024 as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Planned primary completion date changed from 1 Jul 2019 to 1 May 2024 as reported by ClinicalTrials.gov record.